A school teacher diagnosed with immune thrombocytopenic purpura (ITP) presents with petechiae, frequent nosebleeds, and joint pain. The medical team plans to initiate treatment with corticosteroids. Which nursing intervention is most important to prioritize in the care plan to prevent complications associated with her condition?

B) Instruct the patient to avoid activities that could result in injury or bruising.

A) Encourage the patient to maintain a high-fluid diet to prevent dehydration.

B) Instruct the patient to avoid activities that could result in injury or bruising.

C) Administer ibuprofen as needed to manage joint pain.

D) Monitor the patient's blood pressure closely to detect hypertension.

A school teacher has been diagnosed with immune thrombocytopenic purpura (ITP) characterized by severe thrombocytopenia. The clinical team plans to initiate treatment with corticosteroids. Which nursing intervention is most appropriate to minimize the risk of bleeding complications in this patient?

C) Advise the patient to use a soft-bristle toothbrush and avoid flossing.

A) Encourage the patient to maintain a high-fiber diet to prevent constipation.

B) Instruct the patient to apply warm compresses to areas of petechiae.

C) Advise the patient to use a soft-bristle toothbrush and avoid flossing.

D) Recommend the patient engage in high-impact exercises to improve circulation.

A patient diagnosed with immune thrombocytopenic purpura (ITP) is receiving corticosteroid therapy but continues to experience joint pain and petechiae. What should be the nurse's priority intervention to assist in managing the patient's ongoing symptoms?

B) Educate the patient on the importance of avoiding NSAIDs and aspirin.

A) Encourage the patient to increase physical activity to improve joint mobility.

B) Educate the patient on the importance of avoiding NSAIDs and aspirin.

C) Instruct the patient to apply warm compresses to the affected joints.

D) Advise the patient to increase dietary calcium intake to strengthen bone health.

A patient with immune thrombocytopenic purpura (ITP) has been on corticosteroid therapy but continues to experience joint pain and petechiae. The healthcare team is considering adjunctive therapy with intravenous immunoglobulin (IVIG). Which nursing intervention is most crucial when planning care for this patient during the initial IVIG treatment?

D) Prepare the patient for potential immediate side effects, such as fever and chills.

A) Monitor the patient's blood pressure closely for signs of hypotension.

B) Educate the patient about the need for increased fluid intake to prevent dehydration.

C) Assess the patient's lung sounds frequently to detect signs of fluid overload.

D) Prepare the patient for potential immediate side effects, such as fever and chills.

A patient receiving intravenous immunoglobulin (IVIG) for thrombocytopenia presents with elevated blood pressure, mild headaches, and nausea. What is the most appropriate nursing intervention to address these symptoms while continuing IVIG therapy?

B) Administer acetaminophen and encourage hydration

A) Administer a diuretic to reduce fluid overload

B) Administer acetaminophen and encourage hydration

C) Discontinue IVIG and notify the healthcare provider

D) Increase corticosteroid dosage to manage symptoms

A patient receiving intravenous immunoglobulin (IVIG) for thrombocytopenia reports mild headaches and nausea. The nurse notes an increase in blood pressure to 145/90 mmHg. Which of the following actions should the nurse prioritize to address these symptoms while continuing IVIG therapy?

C) Evaluate the patient's hydration status and encourage increased oral fluid intake.

A) Administer an antiemetic to control nausea and monitor blood pressure.

B) Increase the rate of IVIG infusion to reduce treatment duration.

C) Evaluate the patient's hydration status and encourage increased oral fluid intake.

D) Suggest discontinuing IVIG therapy due to adverse effects.

A patient with thrombocytopenia has shown a favorable hematological response to IVIG therapy but is now experiencing increased fatigue and shortness of breath with signs of fluid overload. What is the most appropriate nursing intervention to prioritize in this situation?

B) Implement a conservative fluid restriction and monitor daily weights.

A) Increase oral fluid intake to support hydration.

B) Implement a conservative fluid restriction and monitor daily weights.

C) Administer supplemental oxygen to maintain oxygen saturation.

D) Increase corticosteroid dosage to improve respiratory symptoms.

A 68-year-old female patient with thrombocytopenia is being treated with IVIG and corticosteroids. Forty-eight hours post-treatment, she develops symptoms of increased fatigue and shortness of breath on exertion. Physical examination reveals mild jugular venous distention and bilateral crackles at the lung bases. A chest X-ray confirms mild pulmonary edema. Which nursing intervention should the nurse prioritize to address the patient's current condition?

B) Initiate a conservative fluid restriction and administer low-dose diuretics as prescribed.

A) Increase the patient's oxygen flow rate to improve oxygen saturation.

B) Initiate a conservative fluid restriction and administer low-dose diuretics as prescribed.

C) Encourage the patient to increase oral fluid intake to dilute the blood and improve circulation.

D) Advise the patient to perform deep breathing exercises to expand lung capacity.

A patient who has been treated with diuretics for fluid overload presents with sinus tachycardia, palpitations, mild dizziness, and a serum potassium level of 3.1 mEq/L. Which nursing intervention is the most appropriate to prioritize in this situation?

A) Administer potassium supplements to address the hypokalemia.

B) Increase the patient's fluid intake to prevent dehydration.

C) Monitor the patient's blood glucose levels closely.

D) Prepare the patient for immediate cardioversion.

A patient who was recently started on diuretics and fluid restriction for congestive heart failure presents with palpitations, mild dizziness, and a serum potassium level of 3.1 mEq/L. Which of the following interventions should the nurse prioritize to address the patient's electrolyte imbalance?

B) Administer potassium supplements as prescribed.

A) Increase dietary intake of sodium.

B) Administer potassium supplements as prescribed.

C) Restrict fluid intake further.

D) Initiate a low-potassium diet.

thrombocytopenia - Nursing Case Study

Pathophysiology

• Primary mechanism: Decreased platelet production in the bone marrow due to conditions like aplastic anemia or leukemia. These disorders impair the bone marrow's ability to produce sufficient platelets, leading to thrombocytopenia.

• Secondary mechanism: Increased platelet destruction often caused by immune-mediated conditions, such as immune thrombocytopenic purpura (ITP), where the immune system mistakenly targets and destroys platelets.

• Key complication: Increased risk of bleeding and bruising due to insufficient platelets, which are crucial for normal blood clotting, potentially leading to severe hemorrhagic events.

Patient Profile

Demographics:

52-year-old female, school teacher

History:

• Key past medical history: Hypertension, hypothyroidism, and previous episode of viral hepatitis

• Current medications: Lisinopril, Levothyroxine, and occasional use of Ibuprofen for headaches

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Persistent fatigue and easy bruising

• Key symptoms: Petechiae on the lower legs, occasional nosebleeds, and mild joint pain

• Vital signs: Blood pressure 138/88 mmHg, heart rate 102 bpm, respiratory rate 18 breaths per minute, temperature 99.1°F, oxygen saturation 96% on room air

Section 1

As the clinical team proceeds with the initial assessment, further details about the patient’s condition begin to emerge. Physical examination reveals the presence of petechiae not only on the lower legs but also extending to the arms and abdomen, indicating a more widespread distribution of the hemorrhagic signs. The school teacher also reports experiencing more frequent and prolonged episodes of nosebleeds over the past week, which have required her to apply pressure for longer periods to control. Her joint pain, particularly in the knees and elbows, has become more pronounced, raising concerns about potential bleeding into the joints.

To better understand the underlying cause of the thrombocytopenia, the medical team orders a complete blood count (CBC) with differential and a peripheral blood smear. The lab results indicate a significantly reduced platelet count of 28,000/µL (normal range: 150,000-450,000/µL), confirming severe thrombocytopenia. The white blood cell count and hemoglobin levels are within normal limits, which helps rule out some hematologic malignancies. The peripheral blood smear reveals large, immature megakaryocytes, suggesting the bone marrow's compensatory response to increased platelet destruction. These findings align with a suspected diagnosis of immune thrombocytopenic purpura (ITP), given the patient's clinical history and lab results.

With these diagnostic results, the clinical team considers the next steps in management. The focus shifts to stabilizing the patient and preventing further complications. Given her low platelet count and increased risk of bleeding, the team discusses initiating treatment with corticosteroids to suppress the immune-mediated destruction of platelets. Additionally, they consider avoiding the use of medications like Ibuprofen, which could exacerbate bleeding risk due to its antiplatelet effects. The patient is counseled on recognizing signs of severe bleeding and instructed to seek immediate medical attention should these occur. The team plans for close monitoring and follow-up to assess her response to treatment and adjust the management plan as needed.

Section 2

As the clinical team proceeds with managing the patient, they initiate corticosteroid therapy to address the immune-mediated platelet destruction associated with her suspected diagnosis of immune thrombocytopenic purpura (ITP). Within the first 48 hours, the patient reports some improvement in her symptoms, noting a slight reduction in the frequency of nosebleeds. However, during a follow-up visit, the team observes that her petechiae have not significantly diminished and her joint pain persists, particularly in the knees and elbows. This raises concerns about ongoing or worsening bleeding into the joints, which could complicate her mobility and overall quality of life.

Given the patient's persistent symptoms, the medical team decides to further investigate her condition by ordering additional diagnostic tests. They conduct a bone marrow biopsy to assess the bone marrow's platelet production capacity and rule out other potential causes of her thrombocytopenia, such as bone marrow suppression or infiltration. The biopsy results reveal a hyperplastic bone marrow with increased megakaryocytes, consistent with heightened platelet turnover, and support the initial diagnosis of ITP. However, the team also notes the presence of mild reticulin fibrosis, suggesting a longer-standing process that might complicate her treatment response.

In light of these findings and the patient's inadequate response to corticosteroids alone, the clinical team considers adjunctive therapies. They discuss the possibility of introducing intravenous immunoglobulin (IVIG) to provide a more immediate increase in platelet count and alleviate her bleeding symptoms. Additionally, they educate the patient on lifestyle modifications to minimize bleeding risks, such as avoiding contact sports and using a soft-bristled toothbrush. Close monitoring of her platelet count and symptomatology is planned to gauge the effectiveness of the new treatment strategy and guide further management decisions.

Section 3

As the clinical team implements the adjunctive therapy with intravenous immunoglobulin (IVIG), they closely monitor the patient for changes in her condition. Within 24 hours of the IVIG infusion, the patient reports a noticeable decrease in the frequency and severity of her nosebleeds, and her joint pain begins to ease slightly. The team observes a modest increase in her platelet count, rising from a dangerously low 15,000/μL to a more stable 40,000/μL. Despite this initial positive response, the patient's blood pressure is noted to be elevated at 145/90 mmHg, a potential side effect of IVIG that requires monitoring but is not immediately alarming.

However, new complications arise as the patient starts to experience mild headaches and nausea, symptoms that could be attributed to either the IVIG treatment or the persistent thrombocytopenia. These symptoms prompt the team to reassess her overall clinical status. They conduct a thorough neurological examination to rule out intracranial bleeding, given the risk associated with low platelet levels. Fortunately, the examination shows no focal neurological deficits, providing some reassurance. The team also checks for potential signs of fluid overload or renal compromise, as IVIG can sometimes affect kidney function, but her renal panel remains within normal limits, with a creatinine level of 0.9 mg/dL.

In response to these developments, the clinical team decides to maintain the IVIG therapy while concurrently addressing the side effects. They introduce acetaminophen to manage the headaches and encourage adequate hydration to mitigate potential renal strain. They also adjust the corticosteroid dosage to strike a balance between controlling the immune-mediated platelet destruction and minimizing adverse effects. The patient is advised to report any worsening of symptoms immediately, and the team schedules more frequent follow-ups to monitor her progress. This careful management aims to stabilize her condition and prevent further complications as they continue to assess her response to the treatment regimen.

Section 4

As the clinical team continues to monitor the patient's response to the interventions, they observe a notable change in her status 48 hours post-IVIG infusion. The patient's platelet count has risen further to 70,000/μL, indicating a favorable response to the treatment. Despite this improvement in hematological parameters, the patient begins to experience increased fatigue and shortness of breath on exertion, symptoms which prompt a reassessment of her cardiovascular and respiratory status. This change raises concerns about potential fluid overload, a known risk associated with both IVIG therapy and corticosteroid use.

A detailed physical examination reveals mild jugular venous distention and bilateral crackles at the lung bases. Vital signs show a slight increase in blood pressure to 150/92 mmHg and a heart rate of 98 beats per minute. Oxygen saturation remains stable at 95% on room air, but the team decides to perform a chest X-ray to evaluate for pulmonary congestion. The imaging results confirm mild pulmonary edema, necessitating a reevaluation of the patient's fluid management strategy.

In response to these findings, the clinical team decides to implement a conservative fluid restriction and initiate low-dose diuretics to alleviate the edema. They also monitor her electrolyte levels closely to avoid imbalances. The patient's corticosteroid dosage is carefully adjusted to maintain control over platelet destruction while minimizing potential fluid retention. These interventions aim to stabilize her respiratory status and prevent further cardiovascular complications, while the team continues to evaluate the patient’s overall response to the treatment regimen. Continued close monitoring and follow-up are essential as the patient progresses through this challenging phase of her thrombocytopenia management.

Section 5

As the clinical team continues to monitor the patient closely, they observe a further change in her status 24 hours after the initiation of diuretics and fluid restriction. While the patient's respiratory symptoms have shown some improvement, with decreased crackles upon auscultation and the resolution of jugular venous distention, she now reports experiencing palpitations and mild dizziness. A quick assessment reveals a heart rate of 112 beats per minute, indicating sinus tachycardia, and a slight drop in blood pressure to 138/88 mmHg. These symptoms raise concerns about potential electrolyte imbalances, a known complication associated with diuretic therapy.

Laboratory tests are conducted to assess the patient’s electrolyte levels and reveal a serum potassium level of 3.1 mEq/L, indicating hypokalemia. This electrolyte disturbance likely contributes to her cardiac symptoms and requires immediate intervention. The healthcare team promptly decides to administer potassium supplements and adjust her diuretic regimen to include a potassium-sparing diuretic, aiming to correct the imbalance while maintaining effective management of her fluid status. The patient's ECG is also monitored to detect any further cardiac arrhythmias.

The team recognizes the importance of balancing the benefits of fluid reduction with the risk of electrolyte disturbances. They emphasize the need for frequent monitoring of the patient's electrolyte levels and cardiac status to prevent further complications. This careful approach is crucial as they continue to manage her thrombocytopenia while addressing the emerging challenges. The patient’s response to these interventions will be closely observed over the next 48 hours, with the aim of stabilizing her condition and ensuring a safe progression in her treatment plan.